| 51 |
29516618 | Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England. | 2018 Jul |
2 |
| 52 |
29536608 | Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study. | 2018 Jul |
1 |
| 53 |
29549573 | Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions. | 2018 Apr |
1 |
| 54 |
29645341 | Effects on the glucagon response to hypoglycaemia during DPP-4 inhibition in elderly subjects with type 2 diabetes: A randomized, placebo-controlled study. | 2018 Aug |
2 |
| 55 |
29696037 | Pharmacological Treatment in Diabetes Mellitus Type 1 - Insulin and What Else? | 2018 Jan |
1 |
| 56 |
30090931 | Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients. | 2018 Oct 1 |
1 |
| 57 |
30095971 | Disparities in the Efficacy of Metformin in Combination with Dipeptidyl Peptidase-4 Inhibitor as Initial Treatment Stratified by Dosage and Ethnicity: A Meta-Analysis. | 2018 Oct |
5 |
| 58 |
30233191 | Durability of initial antidiabetic monotherapy and subsequent treatment adjustment patterns among newly treated type 2 diabetes patients. | 2018 |
1 |
| 59 |
30249366 | Pharmacokinetic Interactions Between Gemigliptin and Metformin, and Potential Differences in the Pharmacokinetic Profile of Gemigliptin Between the Mexican and Korean Populations: A Randomized, Open-label Study in Healthy Mexican Volunteers. | 2018 Oct |
1 |
| 60 |
30310100 | Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes. | 2018 Oct 11 |
1 |
| 61 |
30322471 | [Recommendations of the main clinical practice guidelines]. | 2018 Jun |
1 |
| 62 |
30646124 | Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative. | 2018 Aug 3 |
1 |
| 63 |
30646315 | Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes. | 2018 Dec 7 |
1 |
| 64 |
27752788 | The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic review of cost-effectiveness studies. | 2017 Nov |
1 |
| 65 |
28026911 | Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care-based cohort study, with economic assessment of patient outcomes. | 2017 May |
3 |
| 66 |
28056431 | Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia. | 2017 Jan |
1 |
| 67 |
28109184 | Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second- and third-line antidiabetic drugs in patients with type 2 diabetes. | 2017 Jul |
1 |
| 68 |
28188318 | PURLs: Need an add-on to metformin? Consider this. | 2017 Jan |
1 |
| 69 |
28323503 | Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS. | 2017 Nov |
1 |
| 70 |
28330386 | The effects of dual-therapy intensification with insulin or dipeptidylpeptidase-4 inhibitor on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A retrospective cohort study. | 2017 Jul |
1 |
| 71 |
28332871 | SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO. | 2017 Jul |
3 |
| 72 |
28403729 | Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil; findings and implications. | 2017 Apr |
1 |
| 73 |
28455750 | Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data. | 2017 Aug |
1 |
| 74 |
28547998 | A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy. | 2017 Oct |
1 |
| 75 |
28701284 | Cost-effectiveness analysis of different dipeptidyl-peptidase 4 inhibitor drugs for treatment of type 2 diabetes mellitus. | 2017 Dec |
1 |
| 76 |
28771933 | Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies. | 2017 Nov |
1 |
| 77 |
28827024 | Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis. | 2017 Sep |
1 |
| 78 |
28923291 | Use of Prohibited Medication, a Potentially Overlooked Confounder in Clinical Trials: Omarigliptin (Once-weekly DPP-4 Inhibitor) Monotherapy Trial in 18- to 45-year-olds. | 2017 Oct |
1 |
| 79 |
29051159 | Metformin Use May Moderate the Effect of DPP-4 Inhibitors on Cardiovascular Outcomes. | 2017 Dec |
2 |
| 80 |
29109662 | Budget Impact of Introducing Linagliptin into Bosnia and Herzegovina Health Insurance Drug Reimbursement List in 2016-2018. | 2017 Sep |
2 |
| 81 |
29188065 | High circulating plasma dipeptidyl peptidase- 4 levels in non-obese Asian Indians with type 2 diabetes correlate with fasting insulin and LDL-C levels, triceps skinfolds, total intra-abdominal adipose tissue volume and presence of diabetes: a case-control study. | 2017 |
1 |
| 82 |
26073221 | [Differential characteristics of type 2 diabetes in the elderly. Role of dipeptidyl peptidase 4 inhibitors]. | 2016 Jan-Feb |
2 |
| 83 |
27040861 | Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis. | 2016 Apr 2 |
2 |
| 84 |
27076180 | Novel Therapeutics for Diabetes: Uptake, Usage Trends, and Comparative Effectiveness. | 2016 Jun |
1 |
| 85 |
27177784 | Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records. | 2016 Sep |
2 |
| 86 |
27282621 | Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register. | 2016 Oct |
1 |
| 87 |
27500523 | Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. | 2016 Sep |
1 |
| 88 |
27570447 | Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects. | 2016 |
3 |
| 89 |
27570448 | Treatment progression in sulfonylurea and dipeptidyl peptidase-4 inhibitor cohorts of type 2 diabetes patients on metformin. | 2016 |
1 |
| 90 |
27627081 | [The effect of antidiabetic treatment on the bone of patients with type 2 diabetes]. | Fall 2016 |
1 |
| 91 |
27734321 | Blood Glucagon Levels Predict the Hemoglobin A1c Response to Saxagliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin. | 2016 Dec |
2 |
| 92 |
27882332 | C-Peptide Levels Predict the Effectiveness of Dipeptidyl Peptidase-4 Inhibitor Therapy. | 2016 |
4 |
| 93 |
27928958 | Short and Long Term Effects of a DPP-4 Inhibitor Versus Bedtime NPH Insulin as ADD-ON Therapy in Patients with Type 2 Diabetes. | 2016 |
1 |
| 94 |
23665884 | Vildagliptin with metformin once-daily regimen-insights from a single-center analysis. | 2015 May-Jun |
3 |
| 95 |
25457473 | Efficacy of vildagliptin and sitagliptin in lowering fasting plasma glucose: Results of a randomized controlled trial. | 2015 Jun |
1 |
| 96 |
25628514 | Combination of linagliptin and metformin for the treatment of patients with type 2 diabetes. | 2015 |
1 |
| 97 |
25736235 | Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes. | 2015 Jun |
3 |
| 98 |
25840943 | The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death. | 2015 Oct |
6 |
| 99 |
25999728 | Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin. | 2015 |
4 |
| 100 |
26173919 | Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. | 2015 Oct |
1 |